Please wait while the formulary information is being retrieved.
METHYLIN (METHYLPHENIDATE HCL)
- Attention-deficit hyperactivity disorder
- Narcolepsy syndrome
methylphenidate 10 mg/5 mL oral solution
- 5 milliliters (10 mg) by oral route 2 times per day with 8 ounces of water 30-45 minutes before meals
methylphenidate 5 mg/5 mL oral solution
- 5 milliliters (5 mg) by oral route 2 times per day with 8 ouncesof water 30-45 minutes before meals
10 mg/5 mL oral solution
- 5 milliliters (10 mg) by oral route 2 times per day with 8 ounces of water 30-45 minutes before meals
5 mg/5 mL oral solution
- 5 milliliters (5 mg) by oral route 2 times per day with 8 ouncesof water 30-45 minutes before meals
Attention-deficit hyperactivity disorder
- 5 milliliters (5 mg) by oral route 3 times per day with 8 ouncesof water 30-45 minutes before meals
- 5 milliliters (5 mg) by oral route 2 times per day with 8 ouncesof water 30-45 minutes before meals
- 10 milliliters (10 mg) by oral route 2 times per day with 8 ounces of water 30-45 minutes before meals
- 10 milliliters (10 mg) by oral route 3 times per day with 8 ounces of water 30-45 minutes before meals
- 5 milliliters (10 mg) by oral route 2 times per day with 8 ounces of water 30-45 minutes before meals
- 5 milliliters (10 mg) by oral route 3 times per day with 8 ounces of water 30-45 minutes before meals
- 15 milliliters (15 mg) by oral route 2 times per day with 8 ounces of water 30-45 minutes before meals
- 15 milliliters (15 mg) by oral route 3 times per day with 8 ounces of water 30-45 minutes before meals
- 10 milliliters (20 mg) by oral route 2 times per day with 8 ounces of water 30-45 minutes before meals
- 10 milliliters (20 mg) by oral route 3 times per day with 8 ounces of water 30-45 minutes before meals
Narcolepsy syndrome
- 5 milliliters (5 mg) by oral route 3 times per day with 8 ouncesof water 30-45 minutes before meals
- 5 milliliters (5 mg) by oral route 2 times per day with 8 ouncesof water 30-45 minutes before meals
- 10 milliliters (10 mg) by oral route 2 times per day with 8 ounces of water 30-45 minutes before meals
- 10 milliliters (10 mg) by oral route 3 times per day with 8 ounces of water 30-45 minutes before meals
- 5 milliliters (10 mg) by oral route 2 times per day with 8 ounces of water 30-45 minutes before meals
- 5 milliliters (10 mg) by oral route 3 times per day with 8 ounces of water 30-45 minutes before meals
- 15 milliliters (15 mg) by oral route 2 times per day with 8 ounces of water 30-45 minutes before meals
- 15 milliliters (15 mg) by oral route 3 times per day with 8 ounces of water 30-45 minutes before meals
- 10 milliliters (20 mg) by oral route 2 times per day with 8 ounces of water 30-45 minutes before meals
- 10 milliliters (20 mg) by oral route 3 times per day with 8 ounces of water 30-45 minutes before meals
- isocarboxazid
- Marplan
- Matulane
- methylene blue (antidote)
- Nardil
- Parnate
- phenelzine
- procarbazine
- tranylcypromine
Contraindicated
- amitriptyline
- amitriptyline-chlordiazepoxide
- amoxapine
- Amrix
- Anafranil
- Azilect
- bromocriptine
- cabergoline
- Cafergot
- clomipramine
- Compound 347
- cyclobenzaprine
- cyclobenzaprine with msm
- Cycloset
- D.h.e.45
- Datscan
- desipramine
- dihydroergotamine
- doxepin
- Eldepryl
- enflurane
- ergoloid
- Ergomar
- ergotamine tartrate
- ergotamine-caffeine
- Forane
- imipramine HCl
- imipramine pamoate
- ioflupane I 123
- isoflurane
- linezolid
- maprotiline
- methylergonovine
- Migergot
- Migranal
- Norpramin
- nortriptyline
- Pamelor
- Parlodel
- perphenazine-amitriptyline
- protriptyline
- Prudoxin
- rasagiline
- selegiline HCl
- sevoflurane
- Silenor
- Sojourn
- Surmontil
- Tabradol
- Terrell
- Tofranil
- Tofranil-pm
- trimipramine
- Ultane
- Vivactil
- Zelapar
- Zonalon
- Zyvox
Severe
Moderate
- None
- 30 day risk period post-myocardial infarction
- Angina
- Cardiac arrhythmia
- Cardiomyopathy
- Congenital long QT syndrome
- Coronary artery disease
- Gilles de la tourette syndrome
- Glaucoma
- Hyperthyroidism
- Lower seizure threshold
- Motor tic disorder
- Structural disorder of heart
- Thyrotoxicosis
Contraindicated
- Acrocyanosis
- Alcoholism
- Anxiety disorder
- Bipolar disorder
- Cerebrovascular accident
- Chronic heart failure
- Drug dependence
- Hypertension
- Manic disorder
- Peripheral vascular disease
- Priapism
- Psychotic disorder
- Raynaud's phenomenon
- Suicidal ideation
- Uncontrolled epilepsy
Severe
Moderate
- Abnormal hepatic function tests
- Anemia
- Leukopenia
METHYLIN (METHYLPHENIDATE HCL)
- Attention-deficit hyperactivity disorder
- Narcolepsy syndrome
- Hypertension
- Tachycardia
- Acute abdominal pain
- Anorexia
- Excitement
- Headache disorder
- Hyperhidrosis
- Insomnia
- Nausea
- Nervousness
- Upper abdominal pain
- Weight loss
- Xerostomia
More Frequent
Severe
Less Severe
- Angina
- Chest pain
- Dyskinesia
- Motor tic disorder
- Skin rash
- Thrombocytopenic disorder
- Aggressive behavior
- Arthralgias
- Cough
- Dizziness
- Drowsy
- Dyspepsia
- Fever
- Irritability
- Pharyngitis
- Tremor
- Upper respiratory infection
- Urticaria
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acute hepatic failure
- Acute myocardial infarction
- Anaphylaxis
- Anemia
- Angioedema
- Bradycardia
- Bullous dermatitis
- Cerebral vasculitis
- Cerebrovascular accident
- Drug-induced psychosis
- Erythema multiforme
- Exfoliative dermatitis
- Extrasystoles
- Growth failure
- Hallucinations
- Hepatocellular damage
- Hyperbilirubinemia
- Idiopathic thrombocytopenic purpura
- Intracerebral hemorrhage
- Leukopenia
- Manic disorder
- Mood changes
- Pancytopenia
- Priapism
- Raynaud's phenomenon
- Rhabdomyolysis
- Seizure disorder
- Suicidal ideation
- Supraventricular tachycardia
- Tonic clonic seizure
- Toxic psychosis
- Ventricular premature beats
Less Severe
- Acute confusion
- Agitation
- Alopecia
- Blurred vision
- Bruxism
- Constipation
- Diarrhea
- Diplopia
- Dysmenorrhea
- Dyspnea
- Erythema
- Fatigue
- Gynecomastia
- Hematuria
- Libido changes
- Logorrhea
- Migraine
- Motion sickness
- Myalgias
- Mydriasis
- Ocular pain
- Palpitations
- Peripheral vasoconstriction
- Pruritus of skin
- Reversible ischemic neurological defect
- Sore throat
- Visual changes
Contraindicated
None
Severe Precaution
Methylphenidate
Risk of sudden death: avoid use in patients with underlying cardiac structural abnormality, arrhythmia, cardiomyopathy, other heart problems. Other risks; growth suppression, behavioral changes, suicidal ideation, new or breakthrough seizure. Not recommended age < 4 years (AAP). Safety and efficacy not established age < 6 years per manufacturer.
- 1 Day – 4 Years
- Risk of sudden death: avoid use in patients with underlying cardiac structural abnormality, arrhythmia, cardiomyopathy, other heart problems. Other risks; growth suppression, behavioral changes, suicidal ideation, new or breakthrough seizure. Not recommended age < 4 years (AAP). Safety and efficacy not established age < 6 years per manufacturer.
Management or Monitoring Precaution
Methylphenidate
Risk of sudden death: avoid use in patients with underlying cardiac structural abnormality, arrhythmia, cardiomyopathy, other heart problems. Monitor appetite, growth, and behavioral changes including suicidal ideation. Rare risk of priapism. Long-term efficacy not established for pediatric patients.
Risk of sudden death: avoid use in patients with underlying cardiac structural abnormality, arrhythmia, cardiomyopathy, other heart problems. Monitor appetite, growth, and behavioral changes including suicidal ideation. Rare risk of priapism. Safety and efficacy not established < 6 years; Per AAP ADHD guidelines, moderate evidence exists that this drug is safe and effective for age > 4 years; weigh risk versus benefit for use.
- 6 Years – 18 Years
- Risk of sudden death: avoid use in patients with underlying cardiac structural abnormality, arrhythmia, cardiomyopathy, other heart problems. Monitor appetite, growth, and behavioral changes including suicidal ideation. Rare risk of priapism. Long-term efficacy not established for pediatric patients.
- 4 Years – 6 Years
- Risk of sudden death: avoid use in patients with underlying cardiac structural abnormality, arrhythmia, cardiomyopathy, other heart problems. Monitor appetite, growth, and behavioral changes including suicidal ideation. Rare risk of priapism. Long-term efficacy not established for pediatric patients.
Methylphenidate (Select)
Risk of sudden death: avoid use in patients with underlying cardiac structural abnormality, arrhythmia, cardiomyopathy, other heart problems. Monitor appetite, growth, and behavioral changes including suicidal ideation. Rare risk of priapism. Long-term efficacy not established for pediatric patients.
Risk of sudden death: avoid use in patients with underlying cardiac structural abnormality, arrhythmia, cardiomyopathy, other heart problems. Monitor appetite, growth, and behavioral changes including suicidal ideation. Rare risk of priapism. Safety and efficacy not established < 6 years; Per AAP ADHD guidelines, moderate evidence exists that this drug is safe and effective for age > 4 years; weigh risk versus benefit for use.
- 6 Years – 18 Years
- Risk of sudden death: avoid use in patients with underlying cardiac structural abnormality, arrhythmia, cardiomyopathy, other heart problems. Monitor appetite, growth, and behavioral changes including suicidal ideation. Rare risk of priapism. Safety and efficacy not established < 6 years; Per AAP ADHD guidelines, moderate evidence exists that this drug is safe and effective for age > 4 years; weigh risk versus benefit for use.
- 4 Years – 6 Years
- Risk of sudden death: avoid use in patients with underlying cardiac structural abnormality, arrhythmia, cardiomyopathy, other heart problems. Monitor appetite, growth, and behavioral changes including suicidal ideation. Rare risk of priapism. Safety and efficacy not established < 6 years; Per AAP ADHD guidelines, moderate evidence exists that this drug is safe and effective for age > 4 years; weigh risk versus benefit for use.
Methylphenidate
- Severity Level:
2
- Additional Notes: Insuf human data; cns stimulants cross placental barrier
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Methylphenidate
Insufficient data available, limited data suggest minimal excretion
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Insufficient data available, limited data suggest minimal excretion |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Methylphenidate
Neuro/Psych-May exacerbate pre-existing insomnia. Cardiovascular-May exacerbate pre-existing or underlying cardiac abnormality, peripheral vasculopathy. Gastrointestinal-Anorexia may cause significant weight loss.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Misuse or abuse of methylphenidate can result in serious (possibly fatal) heart and blood pressure problems. This medication can be habit-forming and should be used cautiously by people who have mental/mood disorders or a substance use disorder (such as overuse of or addiction to drugs/alcohol). Before using this medication, tell your doctor if you have a personal or family history of a substance use disorder.<br /><br />Do not increase your dose, use it more often, or use it for a longer time or in a different way than prescribed. Doing so may result in a decrease in the effect of this drug, drug dependence, or abnormal thoughts/behavior. Your doctor may monitor you for a while after the medication is stopped, especially if you have taken this drug for a long time or in high doses. (See also How to Use section.)
| Attention-deficit hyperactivity disorder | |
| F90 | Attention-deficit hyperactivity disorders |
| F90.0 | Attention-deficit hyperactivity disorder, predominantly inattentive type |
| F90.1 | Attention-deficit hyperactivity disorder, predominantly hyperactive type |
| F90.2 | Attention-deficit hyperactivity disorder, combined type |
| F90.8 | Attention-deficit hyperactivity disorder, other type |
| F90.9 | Attention-deficit hyperactivity disorder, unspecified type |
| Narcolepsy syndrome | |
| G47.4 | Narcolepsy and cataplexy |
| G47.41 | Narcolepsy |
| G47.411 | Narcolepsy with cataplexy |
| G47.419 | Narcolepsy without cataplexy |
| G47.42 | Narcolepsy in conditions classified elsewhere |
| G47.421 | Narcolepsy in conditions classified elsewhere with cataplexy |
| G47.429 | Narcolepsy in conditions classified elsewhere without cataplexy |
| 0-9 | A-Z |
|---|---|
| F90 | Attention-deficit hyperactivity disorders |
| F90.0 | Attention-deficit hyperactivity disorder, predominantly inattentive type |
| F90.1 | Attention-deficit hyperactivity disorder, predominantly hyperactive type |
| F90.2 | Attention-deficit hyperactivity disorder, combined type |
| F90.8 | Attention-deficit hyperactivity disorder, other type |
| F90.9 | Attention-deficit hyperactivity disorder, unspecified type |
| G47.4 | Narcolepsy and cataplexy |
| G47.41 | Narcolepsy |
| G47.411 | Narcolepsy with cataplexy |
| G47.419 | Narcolepsy without cataplexy |
| G47.42 | Narcolepsy in conditions classified elsewhere |
| G47.421 | Narcolepsy in conditions classified elsewhere with cataplexy |
| G47.429 | Narcolepsy in conditions classified elsewhere without cataplexy |
Formulary Reference Tool